Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal of Korean medical science·2026
Same author

Association of Colonoscopy With Colorectal Cancer Incidence Among Persons Aged 40-49 Years: A Nationwide Population-Based Claims Cohort Study.

The American journal of gastroenterology·2026
Same author

Trends in noticing and responses to cigarette and heated tobacco product warnings among Koreans who use tobacco: findings from the 2020-2023 ITC Korea Surveys.

Tobacco control·2026
Same author

A one-day pilot point-prevalence survey of healthcare-associated infections in three Korean hospitals: risk factors, clinical burden, and implications for nationwide surveillance.

The Journal of hospital infection·2026
Same author

1 versus 2 L PEG/Asc for bowel preparation in patients with hematochezia: a multicenter, prospective, randomized, non-inferiority study.

Therapeutic advances in gastroenterology·2026
Same author

Korean Colorectal Cancer Screening Guidelines for Asymptomatic, average-Risk Adults: The 2025 Revision.

Cancer research and treatment·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same journal

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Stratifying osteosarcoma: minimizing and maximizing therapy.

Lisa M Niswander1, Su Young Kim

  • 1Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive,Bethesda, MD 20892, USA.

Current Oncology Reports
|May 18, 2010
PubMed
Summary
This summary is machine-generated.

Osteosarcoma treatment requires risk stratification to personalize therapy. This review explores molecular targets for high-risk osteosarcoma patients, aiming to improve outcomes and minimize side effects.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

  • Orthopedics
  • Oncology
  • Molecular Biology

Background:

  • Newly diagnosed osteosarcoma patients undergo intensive treatment with significant lifestyle impact.
  • While many survive, long-term sequelae of curative therapy are emerging.
  • A substantial portion of patients do not respond to conventional osteosarcoma treatments.

Purpose of the Study:

  • To propose risk stratification for osteosarcoma patient management.
  • To identify therapeutic strategies for high-risk osteosarcoma.
  • To focus on two molecular targets for improved treatment efficacy.

Main Methods:

  • Review of current osteosarcoma treatment strategies.
  • Analysis of patient outcomes based on risk categories.
  • Identification and discussion of specific molecular targets.

Main Results:

  • Risk stratification can optimize treatment intensity, reducing side effects for low-risk patients.
  • Targeted therapies hold promise for improving outcomes in high-risk osteosarcoma.
  • Two specific molecular targets are highlighted for further investigation.

Conclusions:

  • Personalized therapeutic strategies based on risk stratification are crucial for osteosarcoma management.
  • Developing targeted treatments for high-risk osteosarcoma is essential to improve survival rates.
  • Further research into molecular targets can lead to more effective and less toxic osteosarcoma therapies.